Janssen announced the expansion of Russia’s testimony on the use of etravirine for the treatment of infections caused by human immunodeficiency virus – HIV-1 (in combination with other antiretroviral drugs) for children of 6 years. This drug is the first and only second-generation NNRTIs for the treatment of HIV-1 in children older than 6 years.
Extension of indications based on the results of 48-week study PIANO in HIV-positive children. Molecule drug possesses a certain flexibility that provides efficiency even when multiple resistance to HIV. Since the molecule is attached tightly to the active site of the enzyme reverse transcriptase of HIV, the drug is extremely effective even against virus with the presence of mutations of resistance to NNRTIs first generation.